ChemBridge Announces Their New Fragment Library for Screening

ChemBridge Announces Their New Fragment Library for Screening

January 10, 2007

    SAN DIEGO, Jan. 10 /Xinhua-PRNewswire/ -- ChemBridge
has assembled an exemplary collection of small molecules
useful for fragment-based screening: the new Fragment
Library.  The emergence and development of high throughput
X-ray crystallography and NMR methodologies for drug
discovery have contributed widely to the acceptance and
implementation of fragment based screening.  The ability to
detect low affinity binders has proven invaluable in the
introduction and promotion of this aspect of drug discovery
and design.  The Fragment Library set, comprising
approximately 12,000 compounds, was chosen based upon the
commonly accepted Astex "Rule-of-Three" (MW
<300, H-bond donors/acceptors <3, cLogP <3) as
well as the established proprietary ChemBridge substructure
filters.  The set includes compounds with available, as well
as protected, functionality.  All compounds in the
collection are available in stock and may be cherry-picked
or taken as a complete set.

    Upon independent analysis of ChemBridge's Fragment
Library, an industry expert from a well respected
pharmaceutical company regards the collection as both
attractive and diverse, commenting that it is the largest
commercial fragment library currently offered to his
knowledge.

    "The fragment collection has been assembled using
industry standard chemometrics coupled with ChemBridge's
knowledge of small molecule pharmacophore profiling,"
said ChemBridge's Reg Richardson, Ph.D.  "The result
is the largest commercial offering of `discovery
chemistry-relevant' small molecule fragments.  I am certain
the Fragment Library will be valuable to those engaged in
fragment based screening to identify and construct new
chemical entities having excellent lead-like
properties."

    About ChemBridge Corporation

    ChemBridge Corporation, http://www.chembridge.com , is
a leading global discovery chemistry CRO with an impeccable
track record of quality and deliverability.  ChemBridge was
founded in Chicago in 1993 and has grown to a global
company with 350 employees.  ChemBridge has its corporate
headquarters in San Diego, European office in the UK, and a
marketing agency in Japan.  It also operates a large,
state-of-the-art offshore discovery chemistry research site
in Moscow, Russia.  Over 400 pharmaceutical and biotech
companies and universities worldwide have taken advantage
of ChemBridge's portfolio of advanced discovery chemistry
services and products, including its library of 700,000
diverse drug-like small molecule compounds.   


    For more information, please contact: 

     Reg Richardson
     Ph.D. of ChemBridge Corporation
     Tel:   [phone]
     Email: [e-mail] 


SOURCE  ChemBridge Corporation